MDT-AP-0541
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 14.04
- os_event
- true
- age_years
- 11
- sex
- F
- new_clusters
- S2
- umap1_2d
- -0.186457103
- umap2_2d
- -9.272938115
- umap1_3d
- -3.154800075
- umap2_3d
- -1.139204972
- umap3_3d
- 5.410845649
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.480
- MYC_TARGETS_V1+0.480
- OXIDATIVE_PHOSPHORYLATION+0.350
- MITOTIC_SPINDLE+0.310
- MYC_TARGETS_V2+0.310
- ANGIOGENESIS+0.240
- MTORC1_SIGNALING+0.210
- ANDROGEN_RESPONSE+0.180
- APOPTOSIS+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.420
- INTERFERON_GAMMA_RESPONSE-0.270
- ESTROGEN_RESPONSE_EARLY-0.200
- APICAL_SURFACE-0.190
- MYOGENESIS-0.190
- NOTCH_SIGNALING-0.160
- HEME_METABOLISM-0.140
- XENOBIOTIC_METABOLISM-0.120
- APICAL_JUNCTION-0.090
- HEDGEHOG_SIGNALING-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d9eacc36-0ae3-41bd-aef6-503f91cb25aa | — | — | 0.833 |
| 2 | SRR12475133 | — | — | 0.824 |
| 3 | SRR4195653 | — | — | 0.817 |
| 4 | BS_8ZS9F31R | high-grade glioma | — | 0.812 |
| 5 | SRR23036890 | — | — | 0.807 |
| 6 | MNG1179 | — | — | 0.806 |
| 7 | c192c50f-0236-4d28-9343-ce9d9c3ac291 | — | — | 0.801 |
| 8 | SJEPD030399_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.790 |
| 9 | TCGA-DK-A1AC-01A-11R-A13Y-07 | — | — | 0.787 |
| 10 | MNG1011 | — | — | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| HYPOXIA | 0.070 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |